Insights into infant neuroblastomas based on an analysis of neuroblastomas detected by mass screening at 6 months of age in Japan

European Journal of Pediatric Surgery

Volumn 17, Issue 1, 2007, Pages 23-28

  Suita, Sachiyo ^a,b   Tajiri, T ^a   Higashi, M ^a   Tanaka, S ^a   Kinoshita, Y ^a   Takahashi, Y ^a   Tatsuta, K ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Biology; Infantile neuroblastoma; Mass screening

Indexed keywords

PROTEIN TYROSINE KINASE A;

ARTICLE; BIOASSAY; CONTROLLED STUDY; FLUORESCENCE; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; INFANT; INFANT DISEASE; JAPAN; MAJOR CLINICAL STUDY; MASS SCREENING; MORTALITY; NEUROBLASTOMA; ONCOGENE MYC; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT DISEASE;

CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 17; GENE DELETION; GENE DOSAGE; GENE EXPRESSION; HUMANS; INFANT; JAPAN; MASS SCREENING; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PLOIDIES; PROGNOSIS; RECEPTOR, TRKA;

EID: 34547908939     PISSN: 09397248     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-924640     Document Type: Article

References (18)

1. Bessho F, Hashizume K, Nakajo T et al. Mass screening in Japan increased the detection of infants with neuroblastoma without a decrease in cases in older children. J Pediatr 1991 ; 119: 237-241
2. Hachitanda Y, Ishimoto K, Hata J, Shimada H. One hundred neuroblastoma detected through a mass screening system in Japan. Cancer 1994; 74: 3223-3226
3. Matsumura T, Shikata T, Sawada T. Treatment modality for neuroblastoma infants in Japan: Retrospective analysis and future directions. Proceeding of the 31st American Society of Clinical Oncology. J Clin Oncol 1995; 14: 456
4. Oue T, Inoue M, Yoneda A et al. Profile of neuroblastoma detected by mass screening resected after observation without treatment: results of the wait and see pilot study. J Pediatr Surg 2005; 40: 359-363
5. Sawada T, Kidowaki T, Sakamoto I et al. Neuroblastoma: Mass screening for early detection and its prognosis. Cancer 1984; 53: 2731-2735
6. Shimada E, Chatten J, Newton Jr WA, Sachs N, Hamoudi AB, Chiba T et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984; 73: 405-416
7. Suita S, Zaizen Y, Sera Y et al. Mass screening for neuroblastoma: quo vadis? A 9-year experience from the Pediatric Oncology Study Group of the Kyushu area in Japan. J Pediatr Surg 1996; 31: 555-558
8. Suita S, Tajiri T, Akazawa K, Sera Y, Takamatsu H, Mizote H et al. Mass screening for neuroblastoma at 6 months of age: difficult to justify. J Pediatr Surg 1998; 33: 1674-1678
9. Suita S. Mass screening for neuroblastoma in Japan: lessons learned and future directions. J Pediatr Surg 2002; 37: 949-954
10. Suita S, Zaizen Y, Yano H, Akiyama H, Sera Y, Takamatsu H et al. How to deal with advanced cases of neuroblastoma detected by mass screening: a report from the Pediatric Oncology Study Group of the Kyushu area of Japan. J Pediatr Surg 1994; 29: 599-603
11. Suita S, Sawada T, Kaneko M, Tajiri T, Naito M, Hayashi Yet al. The report of the committee for neuroblastoma at the Japanese association of Pediatric Oncology at 1998. Jpn J Pediatr Oncol 1999; 36: 107-117
12. Tanaka S, Tajiri T, Suita S et al. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma. J Pediatr Surg 2004; 39: 63-68
13. Tanaka T, Sugimoto T, Sawada T. Prognostic discrimination among neuroblastomas according to Ha-ras/Trk A gene expression: a comparison of the profiles of neuroblastomas detected clinically and those detected through mass screening. Cancer 1998; 83: 1626-1633
14. Tajiri T, Shono K, Tanaka S et al. Evaluation of genetic heterogeneity in neuroblastoma. Surgery 2002; 131: 283-287
15. Tajiri T, Tanaka S, Shono K et al. Quick quantitative analysis of gene dosages associated with prognosis in neuroblastoma. Cancer Lett 2001; 166: 89-94
16. Tajiri T, Suita S, Takamatsu H et al. Clinical and biologic characteristics for recurring neuroblastoma at mass screening cases in Japan. Cancer 2001; 15: 349-353
17. Yamamoto K, Ohata S, Ito E et al. Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan. J Clin Oncol 2002; 20: 1209-1214
18. Yamamoto K, Hanada R, Tanimura M, Aihara T, Hayashi Y. Natural history of neuroblastoma found by mass screening. Lancet 1997; 349: 1102